Astra Shot Shows 82% Efficacy With U.K.'s Two-Dose Interval.

(Bloomberg) -- AstraZeneca Plc's Covid vaccine showed 82% effectiveness with a three-month gap between two shots, according to a new study that bolsters the U.K.'s controversial decision to adopt an extended dosing interval. When the U.K. approved the vaccine in December, regulators signaled that they thought the discrepancy was more likely linked to the interval between shots than the dosing level. [Extracted from the article]